🇺🇸 ILOPROST TROMETHAMINE in United States

55 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Off Label Use — 10 reports (18.18%)
  2. Encephalopathy — 8 reports (14.55%)
  3. Multiple Organ Dysfunction Syndrome — 7 reports (12.73%)
  4. Right Ventricular Failure — 7 reports (12.73%)
  5. Disease Progression — 4 reports (7.27%)
  6. Drug Interaction — 4 reports (7.27%)
  7. N-Terminal Prohormone Brain Natriuretic Peptide Increased — 4 reports (7.27%)
  8. Product Use In Unapproved Indication — 4 reports (7.27%)
  9. Subdural Haematoma — 4 reports (7.27%)
  10. Cardiac Dysfunction — 3 reports (5.45%)

Source database →

ILOPROST TROMETHAMINE in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is ILOPROST TROMETHAMINE approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for ILOPROST TROMETHAMINE in United States?

Marketing authorisation holder not available in our data.